Telix Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Telix Pharmaceuticals has been growing earnings at an average annual rate of 6.6%, while the Biotechs industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 80.1% per year. Telix Pharmaceuticals's return on equity is 12.2%, and it has net margins of 7.6%.
Key information
6.6%
Earnings growth rate
9.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 80.1% |
| Return on equity | 12.2% |
| Net Margin | 7.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Telix Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 646 | 49 | 175 | 164 |
| 31 Mar 24 | 576 | 32 | 153 | 145 |
| 31 Dec 23 | 503 | 5 | 134 | 129 |
| 30 Sep 23 | 430 | -21 | 102 | 126 |
| 30 Jun 23 | 357 | -48 | 92 | 105 |
| 31 Mar 23 | 249 | -77 | 89 | 91 |
| 31 Dec 22 | 160 | -104 | 87 | 81 |
| 30 Sep 22 | 94 | -111 | 83 | 63 |
| 30 Jun 22 | 29 | -119 | 79 | 45 |
| 31 Mar 22 | 18 | -100 | 63 | 40 |
| 31 Dec 21 | 8 | -81 | 47 | 34 |
| 30 Sep 21 | 7 | -70 | 39 | 31 |
| 30 Jun 21 | 7 | -59 | 32 | 28 |
| 31 Mar 21 | 6 | -52 | 28 | 26 |
| 31 Dec 20 | 5 | -45 | 24 | 23 |
| 30 Sep 20 | 4 | -40 | 22 | 23 |
| 30 Jun 20 | 3 | -36 | 19 | 22 |
| 31 Mar 20 | 3 | -32 | 17 | 22 |
| 31 Dec 19 | 3 | -28 | 16 | 21 |
| 30 Sep 19 | 3 | -23 | 14 | 21 |
| 30 Jun 19 | 2 | -19 | 12 | 20 |
| 31 Mar 19 | 1 | -16 | 11 | 19 |
| 31 Dec 18 | 0 | -14 | 9 | 19 |
| 30 Sep 18 | 0 | -12 | 8 | 14 |
| 30 Jun 18 | 0 | -10 | 7 | 9 |
| 31 Mar 18 | 0 | -8 | 5 | 6 |
| 31 Dec 17 | 0 | -6 | 4 | 3 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
Quality Earnings: T3X has high quality earnings.
Growing Profit Margin: T3X became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: T3X has become profitable over the past 5 years, growing earnings by 6.6% per year.
Accelerating Growth: T3X has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: T3X has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: T3X's Return on Equity (12.2%) is considered low.